Is the Pharma - Others sector outperforming NIFTY 500?
The 52-week sector comparison is unavailable. 7 of 10 covered companies currently have positive Mansfield relative strength versus NIFTY 500.
20-quarter listed-company comparison
Pharma - Others Stocks in India
Pharma - Others: Unichem Laboratories Ltd owns the largest revenue base; JOJO Ltd has the fastest current growth.
Nifty Pharma - Others Index — Constituents & Performance
The Pharma - Others companies below are the listed Indian Pharma - Others universe this page tracks — the same constituent set people search for as the Nifty Pharma - Others index. Every figure is equal-weighted across those companies, so one large constituent cannot set the reading. Each number carries its own as-of date.
The sector itself · before any single company
How has Pharma - Others moved against NIFTY 500?
The line below covers 5.1 years. Over the most recent two of them this sector is 19% ahead of NIFTY 500. Earnings across its companies fell 3% on average over the last four reported quarters. It has been ahead of NIFTY 500 on a rolling three-month view for 15 weeks running.
FADING · −2 in 4w✓Price up, without the fundamentals confirming4 of 7 companies ahead of NIFTY 500 by 5% or more over three months2 are 20% or more behind over a year while earnings grew 20% or more
RS ↑15w · 5/7 >200d (+1) · 4/7 lead (−2) · EPS 6/7↑
Pharma - Others, equal-weighted, based at 200
NIFTY 500, same base, same start
trailing 12-month earnings per share rising
falling
Strength anatomy
Broad but lateHow much of the sector is participating, how recently, and whether the movers score well.
Together4 of 7 stocks moving
Fresh0 crossed in the last 4 weeks
Backed by scoresmovers score −1 vs the sector average
Down the cap ladder — bar is now, tick is four weeks ago
Large
2/20
Mid
1/2−1
Small
1/3−1
Participation is not spreading downward this month; the larger companies are still carrying most of it.
Both lines start at 200 in the same week, so the distance between them is the whole story: the sector line is an equal-weighted index of its 7 companies. The bars underneath are trailing 12-month earnings per share, one bar per reported quarter, each member rebased to 100 at the start and the sector taking the median — so a price line pulling away from flat bars is a re-rating, not earnings. A bar turns red when that figure is lower than the quarter before. Rules are fixed and applied identically everywhere on this site: ahead by 5% or more over three months, or behind by 20% or more over a year while earnings grew 20% or more. Hover any point to read both values and the gap. This is a description of what the numbers did, not advice.
Sector relative strength · before individual stocks
Is Pharma - Others outperforming NIFTY 500?
The 52-week comparison of Pharma - Others against NIFTY 500 is not available from the current market series. 7 of 10 covered companies currently beat NIFTY on Mansfield relative strength, so leadership inside the sector is selective. Shukra Pharmaceuticals Ltd is the strongest against the sector itself at +49.8%. Readings are as of 2026-07-19.
—Sector vs NIFTY 500 · 13 weeks
—Sector vs NIFTY 500 · 52 weeks
7/10Stocks leading NIFTY 500
5/10Stocks leading sector
Sector metric: 44.7 as of 2026-07-19 · BROADENING · falling.
The central tension: the companies with the most scale are not necessarily the companies creating the most change.
Start with scale. Then earnings trajectory. Then business quality. Only after those three agree should price leadership carry much weight.
Bottom line
The 52-week sector comparison is unavailable. 7 of 10 covered companies currently have positive Mansfield relative strength versus NIFTY 500. Unichem Laboratories Ltd leads with revenue of ₹2,202 crore, based on 10 of 10 comparable companies through Mar 2026. JOJO Ltd has the fastest current revenue growth at 100%, across 10 of 10 comparable companies.
Which Pharma - Others company is largest by revenue?
Unichem Laboratories Ltd leads with revenue of ₹2,202 crore, based on 10 of 10 comparable companies through Mar 2026.
Which Pharma - Others company is growing fastest?
JOJO Ltd has the fastest current revenue growth at 100%, across 10 of 10 comparable companies.
Which Pharma - Others company has the strongest 4-Factor Sector Score?
JOJO Ltd ranks first at 65.6/100 with 70.2% evidence confidence. The score prioritizes research; it is not a buy recommendation.
Which Pharma - Others company reports the most CAPEX?
Remus Pharmaceuticals Ltd reports the largest latest CAPEX at ₹11 crore, with 1 of 10 companies comparable.
Which Pharma - Others company has the least gross debt?
Syncom Formulations (India) Ltd has the lowest comparable gross debt at ₹1 crore. Sun Pharma Advanced Research Company Ltd has the highest at ₹559 crore.
How much history does this Pharma - Others comparison include?
The page compares up to 20 reported quarters per company for fundamentals, CAPEX, debt and valuation, ending Mar 2026. Missing observations remain blank rather than being estimated.
How is the 4-Factor Sector Score calculated?
The four visible contributions add directly: growth and earnings up to 35 points, capital efficiency up to 25, valuation up to 20, and relative strength up to 20. Missing or stale evidence moves only the affected contribution toward neutral.
Companies
10
complete canonical membership
Combined market value
₹20.8K Cr
Sun Pharma Advanced Research Company Ltd
Revenue growing
10/10
positive TTM year-on-year growth
Beating NIFTY 500
7/10
positive Mansfield relative strength
Global company selection
00 · research priority, made explicit
4-Factor Sector Score
An additive sector-relative research score. The four displayed point contributions always equal the total: Growth & earnings (35), Capital efficiency (25), Valuation (20), and Relative strength (20). Missing or stale evidence is absorbed inside the affected factor, never applied as a hidden adjustment.
Growth & earnings · 35%Capital efficiency · 25%Valuation · 20%Relative strength · 20%
JOJO Ltd has the strongest current balance of earnings trajectory, business quality, valuation and price confirmation, with 70.2% evidence confidence.
TTK Healthcare Ltd looks inexpensive relative to peers or its own history, but its earnings trajectory has not yet earned the valuation signal.
Madhuveer Com 18 Network Ltd has stronger price confirmation than earnings confirmation; that is a research prompt, not permission to chase.
Missing observations are not scored as bad. Their missing weight lowers confidence and pulls the final score toward neutral. PEG is guarded: positive earnings, positive 5–60% three-year EPS growth, and a positive P/E are required.
1. JOJO Ltd · 531910
65.6/100 · Favorable setup · 70% evidence
Exact sum: 30 + 14 + 8.9 + 12.7 = 65.6
Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
30.0/35Growth & earnings
Revenue 100% · PAT 100% · OPM change 115.2 pp
95% evidence
14.0/25Capital efficiency
ROCE 17% · debt/equity 0.06×
80% evidence
8.9/20Valuation
P/E 156× · PEG —
15% evidence
12.7/20Relative strength
RS sector 4.3% · RS bench 13.5% · 1Y 20.4%
70% evidence
2. Shukra Pharmaceuticals Ltd · SHUKRAPHAR
64.5/100 · Mixed-positive evidence · 66% evidence
Exact sum: 21.8 + 16.8 + 9.3 + 16.6 = 64.5
Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
21.8/35Growth & earnings
Revenue 100% · PAT 100% · OPM change 32 pp
83% evidence
16.8/25Capital efficiency
ROCE 21.8% · debt/equity 0.06×
80% evidence
9.3/20Valuation
P/E 62.2× · PEG —
15% evidence
16.6/20Relative strength
RS sector 49.8% · RS bench 40.2% · 1Y 92.1%
70% evidence
3. Sun Pharma Advanced Research Company Ltd · SPARC
61.6/100 · Mixed-positive evidence · 79% evidence
Exact sum: 17.7 + 16.3 + 9.2 + 18.4 = 61.6
Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
17.7/35Growth & earnings
Revenue 100% · PAT 100% · OPM change 292 pp
71% evidence
16.3/25Capital efficiency
ROCE 164% · debt/equity 0.42×
95% evidence
9.2/20Valuation
P/E 4.5× · PEG —
50% evidence
18.4/20Relative strength
RS sector 23.4% · RS bench 51.8% · 1Y 46.1%
100% evidence
4. Jenburkt Pharmaceuticals Ltd · 524731
52.2/100 · Mixed-positive evidence · 83% evidence
Exact sum: 16.9 + 20.3 + 10.1 + 4.9 = 52.2
Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
16.9/35Growth & earnings
Revenue 11.8% · PAT 6.1% · OPM change 6 pp
95% evidence
20.3/25Capital efficiency
ROCE 27.2% · debt/equity 0.01×
80% evidence
10.1/20Valuation
P/E 13.2× · PEG —
50% evidence
4.9/20Relative strength
RS sector -15.3% · RS bench 0.4% · 1Y -13.2%
100% evidence
5. Syncom Formulations (India) Ltd · SYNCOMF
50.8/100 · Mixed-positive evidence · 87% evidence
Exact sum: 20.9 + 18.9 + 11 + 0 = 50.8
Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
20.9/35Growth & earnings
Revenue 4.9% · PAT 54% · OPM change 4 pp
95% evidence
18.9/25Capital efficiency
ROCE 26.8% · debt/equity 0×
95% evidence
11.0/20Valuation
P/E 16.1× · PEG —
50% evidence
0.0/20Relative strength
RS sector -28.2% · RS bench -10% · 1Y -28.1%
100% evidence
6. Remus Pharmaceuticals Ltd · REMUS
50.2/100 · Mixed-positive evidence · 70% evidence
Exact sum: 19.8 + 13.5 + 11.9 + 5 = 50.2
Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
19.8/35Growth & earnings
Revenue 100% · PAT 100% · OPM change 0 pp
48% evidence
13.5/25Capital efficiency
ROCE 16.8% · debt/equity 0.08×
95% evidence
11.9/20Valuation
P/E 22.9× · PEG —
50% evidence
5.0/20Relative strength
RS sector -21% · RS bench -1.2% · 1Y -25%
100% evidence
7. Madhuveer Com 18 Network Ltd · MADHUVEER
48.3/100 · Mixed-negative evidence · 66% evidence
Exact sum: 15.6 + 10.3 + 8.5 + 13.9 = 48.3
Decision use: Price leads the evidence: RS versus the benchmark is 6.3%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
15.6/35Growth & earnings
Revenue 68.7% · PAT 12.8% · OPM change 18.4 pp
83% evidence
10.3/25Capital efficiency
ROCE -1.1% · debt/equity 0.06×
80% evidence
8.5/20Valuation
P/E 660× · PEG —
15% evidence
13.9/20Relative strength
RS sector 14.3% · RS bench 6.3% · 1Y 9.1%
70% evidence
8. Panacea Biotec Ltd · PANACEABIO
44.8/100 · Mixed-negative evidence · 65% evidence
Exact sum: 20.4 + 4.9 + 10 + 9.5 = 44.8
Decision use: Balanced evidence: keep at normal research priority and require another comparable period before raising conviction.
20.4/35Growth & earnings
Revenue 14.4% · PAT 17.9% · OPM change 21.8 pp
74% evidence
4.9/25Capital efficiency
ROCE -2.4% · debt/equity 0.03×
100% evidence
10.0/20Valuation
P/E — · PEG —
0% evidence
9.5/20Relative strength
RS sector -10.2% · RS bench 33.9% · 1Y 27.9%
70% evidence
9. Unichem Laboratories Ltd · UNICHEMLAB
44.4/100 · Mixed-negative evidence · 76% evidence
Exact sum: 10.3 + 7.2 + 9.6 + 17.3 = 44.4
Decision use: Price leads the evidence: RS versus the benchmark is 34.1%, but earnings trajectory is weak. Wait for revenue and profit confirmation.
10.3/35Growth & earnings
Revenue 4.4% · PAT 83.3% · OPM change -6 pp
95% evidence
7.2/25Capital efficiency
ROCE 4.1% · debt/equity 0.18×
80% evidence
9.6/20Valuation
P/E 46.2× · PEG —
15% evidence
17.3/20Relative strength
RS sector 7.5% · RS bench 34.1% · 1Y -6.2%
100% evidence
10. TTK Healthcare Ltd · TTKHLTCARE
40.3/100 · Mixed-negative evidence · 81% evidence
Exact sum: 10.4 + 11.3 + 13.8 + 4.8 = 40.3
Decision use: Cheap but unconfirmed: require improving earnings before treating the valuation as an opportunity.
10.4/35Growth & earnings
Revenue 7% · PAT -19.5% · OPM change -1 pp
95% evidence
11.3/25Capital efficiency
ROCE 8% · debt/equity 0.02×
95% evidence
13.8/20Valuation
P/E 21.6× · PEG —
50% evidence
4.8/20Relative strength
RS sector -20.5% · RS bench -4.3% · 1Y -26%
70% evidence
01 · compare level, then change
Revenue Scale & Growth Durability
Unichem Laboratories Ltd has the highest Revenue among the 10 Pharma - Others companies compared here, at ₹2,202 crore. Sun Pharma Advanced Research Company Ltd is next at ₹1,879 crore. JOJO Ltd has the highest Revenue growth at the 100% top of the scoring scale, so level and change sit with different companies.
What the numbers say: Unichem Laboratories Ltd is the scale leader at ₹2,202 crore, 17.2% ahead of Sun Pharma Advanced Research Company Ltd. JOJO Ltd's growth is stored at the ≥100% scoring cap; the uncapped TTM change is 446.9% from a ₹24 crore base, with 15 reported observations in the 20-quarter window. Treat the growth leader as an acceleration candidate, not as equally proven scale.
LeaderUnichem Laboratories Ltd · ₹2,202 crore
Gap17.2% versus #2 · Sun Pharma Advanced Research Company Ltd
Persistence6/8 recent comparable periods
Coverage10/10 companies · 145 observations
Investor read: Unichem Laboratories Ltd is the scale benchmark; JOJO Ltd is the acceleration watch. Promote the challenger only if growth persists and converts into margin and returns.
This conclusion weakens if: Unichem Laboratories Ltd's growth falls below JOJO Ltd's for two consecutive comparable reports while operating margin also compresses.
Revenue is compared on a common reported-currency basis. Growth is year-on-year, so seasonality does not masquerade as progress.
Revenuelargest
1Unichem Laboratories Ltd UNICHEMLAB₹2.2K Cr
2Sun Pharma Advanced Research Company Ltd SPARC₹1.9K Cr
3Remus Pharmaceuticals Ltd REMUS⚠ unverified₹1.5K Cr
4TTK Healthcare Ltd TTKHLTCARE⚠ unverified₹857 Cr
5Panacea Biotec Ltd PANACEABIO₹640 Cr
Revenue growthfastest growers
1JOJO Ltd 531910100%
2Remus Pharmaceuticals Ltd REMUS⚠ unverified100%
3Shukra Pharmaceuticals Ltd SHUKRAPHAR100%
4Sun Pharma Advanced Research Company Ltd SPARC100%
5Madhuveer Com 18 Network Ltd MADHUVEER69%
Revenue · company comparison
10/10 level · 10/10 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Revenue | Revenue growth | Reported |
|---|---|---|---|
| Sun Pharma Advanced Research Company Ltd SPARC | ₹1.9K Cr | 6,763% | Mar 2026 |
| Unichem Laboratories Ltd UNICHEMLAB | ₹575 Cr | -2.0% | Mar 2026 |
| Remus Pharmaceuticals Ltd REMUS⚠ unverified | ₹453 Cr | 30% | Mar 2026 |
| TTK Healthcare Ltd TTKHLTCARE⚠ unverified | ₹218 Cr | 15% | Mar 2026 |
| Panacea Biotec Ltd PANACEABIO | ₹167 Cr | 26% | Mar 2026 |
| Syncom Formulations (India) Ltd SYNCOMF⚠ unverified | ₹135 Cr | -9.4% | Mar 2026 |
| Jenburkt Pharmaceuticals Ltd 524731 | ₹45 Cr | 9.8% | Mar 2026 |
| Shukra Pharmaceuticals Ltd SHUKRAPHAR | ₹39 Cr | 255% | Dec 2025 |
| JOJO Ltd 531910 | ₹13 Cr | 781% | Mar 2026 |
| Madhuveer Com 18 Network Ltd MADHUVEER | ₹8 Cr | 257% | Dec 2025 |
Full 20-quarter history · every available company
Revenue · reported quarter history
Jenburkt Pharmaceuticals Ltd · 524731
—
—
—
—
—
—
—
₹35 Cr
₹29 Cr
₹38 Cr
₹36 Cr
₹39 Cr
₹33 Cr
₹41 Cr
₹37 Cr
₹41 Cr
₹36 Cr
₹46 Cr
₹43 Cr
₹45 Cr
JOJO Ltd · 531910
—
—
—
—
—
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹5 Cr
₹0 Cr
₹1 Cr
₹2 Cr
₹1 Cr
₹2 Cr
₹1 Cr
₹8 Cr
₹13 Cr
Madhuveer Com 18 Network Ltd · MADHUVEER
—
—
—
—
—
—
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹5 Cr
₹0 Cr
₹1 Cr
₹2 Cr
₹1 Cr
₹2 Cr
₹1 Cr
₹8 Cr
—
Panacea Biotec Ltd · PANACEABIO
₹132 Cr
₹232 Cr
₹156 Cr
₹141 Cr
₹111 Cr
₹105 Cr
₹115 Cr
₹129 Cr
₹129 Cr
₹143 Cr
₹151 Cr
₹136 Cr
₹116 Cr
₹147 Cr
₹163 Cr
₹133 Cr
₹167 Cr
₹141 Cr
₹165 Cr
₹167 Cr
Remus Pharmaceuticals Ltd · REMUS⚠ unverified
—
—
—
₹14 Cr
—
₹20 Cr
—
₹25 Cr
—
₹29 Cr
—
₹185 Cr
—
₹273 Cr
—
₹348 Cr
—
₹400 Cr
—
₹453 Cr
Shukra Pharmaceuticals Ltd · SHUKRAPHAR
—
—
—
—
—
—
₹2 Cr
₹46 Cr
₹20 Cr
₹25 Cr
₹19 Cr
₹11 Cr
₹3 Cr
₹6 Cr
₹11 Cr
₹13 Cr
₹5 Cr
₹6 Cr
₹39 Cr
—
Sun Pharma Advanced Research Company Ltd · SPARC
₹22 Cr
₹28 Cr
₹62 Cr
₹25 Cr
₹28 Cr
₹32 Cr
₹131 Cr
₹48 Cr
₹24 Cr
₹21 Cr
₹14 Cr
₹17 Cr
₹17 Cr
₹13 Cr
₹15 Cr
₹27 Cr
₹10 Cr
₹8 Cr
₹8 Cr
₹1.9K Cr
Syncom Formulations (India) Ltd · SYNCOMF⚠ unverified
—
—
—
—
—
—
₹57 Cr
₹61 Cr
₹60 Cr
₹64 Cr
₹65 Cr
₹75 Cr
₹87 Cr
₹102 Cr
₹128 Cr
₹149 Cr
₹117 Cr
₹122 Cr
₹115 Cr
₹135 Cr
TTK Healthcare Ltd · TTKHLTCARE⚠ unverified
—
—
—
—
—
—
₹183 Cr
₹180 Cr
₹202 Cr
₹186 Cr
₹184 Cr
₹181 Cr
₹208 Cr
₹198 Cr
₹205 Cr
₹190 Cr
₹226 Cr
₹204 Cr
₹209 Cr
₹218 Cr
Unichem Laboratories Ltd · UNICHEMLAB
—
—
—
—
—
—
₹302 Cr
₹402 Cr
₹423 Cr
₹416 Cr
₹466 Cr
₹432 Cr
₹483 Cr
₹507 Cr
₹533 Cr
₹587 Cr
₹527 Cr
₹579 Cr
₹521 Cr
₹575 Cr
Revenue growth · reported quarter history
Jenburkt Pharmaceuticals Ltd · 524731
—
—
—
—
—
—
—
—
—
—
—
11%
14%
7.9%
2.8%
5.1%
9.1%
12%
16%
9.8%
JOJO Ltd · 531910
—
—
—
—
—
—
—
—
—
800%
150%
—
-33%
611%
4,460%
-69%
4,375%
130%
257%
781%
Madhuveer Com 18 Network Ltd · MADHUVEER
—
—
—
—
—
—
—
—
—
—
150%
—
-33%
611%
4,460%
-69%
4,375%
130%
257%
—
Panacea Biotec Ltd · PANACEABIO
—
—
—
—
-16%
-55%
-26%
-8.6%
16%
36%
31%
5.8%
-10%
3.0%
8.6%
-2.9%
44%
-4.2%
1.0%
26%
Remus Pharmaceuticals Ltd · REMUS⚠ unverified
—
—
—
—
—
—
—
79%
—
45%
—
640%
—
841%
—
88%
—
47%
—
30%
Shukra Pharmaceuticals Ltd · SHUKRAPHAR
—
—
—
—
—
—
—
—
—
—
850%
-76%
-85%
-76%
-42%
18%
67%
0.0%
255%
—
Sun Pharma Advanced Research Company Ltd · SPARC
—
—
—
—
27%
14%
111%
92%
-14%
-34%
-89%
-65%
-29%
-38%
7.1%
59%
-41%
-38%
-47%
6,763%
Syncom Formulations (India) Ltd · SYNCOMF⚠ unverified
—
—
—
—
—
—
—
—
—
—
14%
23%
45%
59%
97%
99%
34%
20%
-10%
-9.4%
TTK Healthcare Ltd · TTKHLTCARE⚠ unverified
—
—
—
—
—
—
—
—
—
—
0.6%
0.6%
3.0%
6.5%
11%
5.0%
8.7%
3.0%
2.0%
15%
Unichem Laboratories Ltd · UNICHEMLAB
—
—
—
—
—
—
—
—
—
—
54%
7.5%
14%
22%
14%
36%
9.1%
14%
-2.3%
-2.0%
02 · compare level, then change
Operating Economics & Margin Trend
Sun Pharma Advanced Research Company Ltd has the highest OPM among the 10 Pharma - Others companies compared here, at 96%. Madhuveer Com 18 Network Ltd is next at 69.7%. The same company also holds the highest Margin change, at +292 percentage points. 10 of 10 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: Sun Pharma Advanced Research Company Ltd leads both opm at 96% and margin change at +292 percentage points.
LeaderSun Pharma Advanced Research Company Ltd · 96%
Gap37.7% versus #2 · Madhuveer Com 18 Network Ltd
Persistence4/8 recent comparable periods
Coverage10/10 companies · 180 observations
Investor read: Sun Pharma Advanced Research Company Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current margin change signal.
Operating margin compares operating profit with revenue. Improvement is measured in percentage points, not percentage growth.
OPMhighest
1Sun Pharma Advanced Research Company Ltd SPARC96%
2Madhuveer Com 18 Network Ltd MADHUVEER70%
3Shukra Pharmaceuticals Ltd SHUKRAPHAR69%
4JOJO Ltd 53191048%
5Jenburkt Pharmaceuticals Ltd 52473132%
Margin changefastest expanders
1Sun Pharma Advanced Research Company Ltd SPARC+292.0 pp
2JOJO Ltd 531910+115.2 pp
3Shukra Pharmaceuticals Ltd SHUKRAPHAR+32.0 pp
4Panacea Biotec Ltd PANACEABIO+21.8 pp
5Madhuveer Com 18 Network Ltd MADHUVEER+18.4 pp
Operating margin · company comparison
10/10 level · 10/10 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | OPM | Margin change | Reported |
|---|---|---|---|
| Sun Pharma Advanced Research Company Ltd SPARC | 96% | +292.0 pp | Mar 2026 |
| Madhuveer Com 18 Network Ltd MADHUVEER | 70% | +18.4 pp | Dec 2025 |
| Shukra Pharmaceuticals Ltd SHUKRAPHAR | 69% | +32.0 pp | Dec 2025 |
| JOJO Ltd 531910 | 48% | +115.2 pp | Mar 2026 |
| Jenburkt Pharmaceuticals Ltd 524731 | 32% | +6.0 pp | Mar 2026 |
| Syncom Formulations (India) Ltd SYNCOMF⚠ unverified | 16% | +4.0 pp | Mar 2026 |
| Unichem Laboratories Ltd UNICHEMLAB | 8.0% | −6.0 pp | Mar 2026 |
| Remus Pharmaceuticals Ltd REMUS⚠ unverified | 7.0% | 0.0 pp | Mar 2026 |
| TTK Healthcare Ltd TTKHLTCARE⚠ unverified | 5.0% | −1.0 pp | Mar 2026 |
| Panacea Biotec Ltd PANACEABIO | 1.5% | +21.8 pp | Mar 2026 |
Full 20-quarter history · every available company
OPM · reported quarter history
Jenburkt Pharmaceuticals Ltd · 524731
20%
29%
21%
16%
23%
24%
20%
21%
24%
24%
20%
25%
29%
28%
24%
26%
25%
29%
17%
32%
JOJO Ltd · 531910
—
—
91%
-25%
17%
100%
50%
0.0%
17%
-222%
20%
44%
—
-52%
51%
-67%
-8.4%
-89%
70%
48%
Madhuveer Com 18 Network Ltd · MADHUVEER
—
—
91%
-25%
17%
100%
50%
—
17%
-222%
20%
44%
—
-52%
51%
-67%
-8.4%
-89%
70%
—
Panacea Biotec Ltd · PANACEABIO
-1.2%
2.6%
7.6%
-21%
-72%
-3.7%
-7.5%
-4.4%
-8.0%
-2.5%
-0.1%
-4.4%
-12%
4.8%
4.9%
-20%
-0.7%
-13%
7.1%
1.5%
Remus Pharmaceuticals Ltd · REMUS⚠ unverified
—
—
—
11%
—
23%
—
23%
—
32%
—
11%
—
8.0%
—
7.0%
—
7.0%
—
7.0%
Shukra Pharmaceuticals Ltd · SHUKRAPHAR
7.1%
-65%
13%
18%
15%
13%
12%
8.0%
2.0%
21%
51%
41%
25%
12%
37%
55%
24%
-7.0%
69%
—
Sun Pharma Advanced Research Company Ltd · SPARC
-245%
-196%
-18%
-264%
-275%
-198%
12%
-188%
-427%
-432%
-740%
-639%
-555%
-800%
-494%
-196%
-540%
-836%
-670%
96%
Syncom Formulations (India) Ltd · SYNCOMF⚠ unverified
14%
11%
8.5%
3.5%
6.8%
7.9%
10%
10%
11%
10%
11%
13%
12%
12%
12%
12%
14%
15%
18%
16%
TTK Healthcare Ltd · TTKHLTCARE⚠ unverified
4.6%
1.8%
5.3%
3.0%
2.0%
2.4%
5.0%
8.0%
5.0%
5.0%
3.0%
7.0%
3.0%
4.0%
4.0%
6.0%
1.0%
3.0%
3.0%
5.0%
Unichem Laboratories Ltd · UNICHEMLAB
-0.6%
2.2%
-0.5%
19%
-0.3%
-5.6%
-14%
4.0%
7.0%
2.0%
7.0%
6.0%
8.0%
11%
16%
14%
4.0%
11%
9.0%
8.0%
Margin change · reported quarter history
Jenburkt Pharmaceuticals Ltd · 524731
+16.2 pp
+5.4 pp
−0.9 pp
−0.6 pp
+3.7 pp
−4.9 pp
−0.9 pp
+4.6 pp
+0.6 pp
−0.0 pp
−0.2 pp
+4.0 pp
+5.0 pp
+4.0 pp
+4.0 pp
+1.0 pp
−4.0 pp
+1.0 pp
−7.0 pp
+6.0 pp
JOJO Ltd · 531910
—
—
+107.6 pp
−25.0 pp
—
—
−40.9 pp
+25.0 pp
0.0 pp
−322.2 pp
−30.0 pp
+44.1 pp
−1,716.7 pp
+170.7 pp
+31.3 pp
−111.2 pp
+1,691.6 pp
−37.6 pp
+18.4 pp
+115.2 pp
Madhuveer Com 18 Network Ltd · MADHUVEER
—
—
+107.6 pp
−25.0 pp
—
—
−40.9 pp
—
0.0 pp
−322.2 pp
−30.0 pp
—
−1,716.7 pp
+170.7 pp
+31.3 pp
−111.2 pp
+1,691.6 pp
−37.6 pp
+18.4 pp
—
Panacea Biotec Ltd · PANACEABIO
−17.4 pp
−18.1 pp
−3.0 pp
−22.0 pp
−70.9 pp
−6.2 pp
−15.1 pp
+17.1 pp
+64.1 pp
+1.2 pp
+7.4 pp
−0.0 pp
−4.1 pp
+7.2 pp
+5.0 pp
−15.9 pp
+11.4 pp
−17.4 pp
+2.2 pp
+21.8 pp
Remus Pharmaceuticals Ltd · REMUS⚠ unverified
—
—
—
—
—
—
—
+12.0 pp
—
+9.0 pp
—
−12.0 pp
—
−24.0 pp
—
−4.0 pp
—
−1.0 pp
—
0.0 pp
Shukra Pharmaceuticals Ltd · SHUKRAPHAR
−14.5 pp
−85.9 pp
+3.4 pp
+6.9 pp
+7.5 pp
+77.7 pp
−0.8 pp
−9.7 pp
−12.6 pp
+8.4 pp
+39.0 pp
+33.0 pp
+23.0 pp
−9.0 pp
−14.0 pp
+14.0 pp
−1.0 pp
−19.0 pp
+32.0 pp
—
Sun Pharma Advanced Research Company Ltd · SPARC
−277.3 pp
+270.8 pp
+270.5 pp
−83.9 pp
−30.3 pp
−2.3 pp
+30.5 pp
+75.6 pp
−152.2 pp
−233.5 pp
−752.3 pp
−451.0 pp
−128.0 pp
−368.0 pp
+246.0 pp
+443.0 pp
+15.0 pp
−36.0 pp
−176.0 pp
+292.0 pp
Syncom Formulations (India) Ltd · SYNCOMF⚠ unverified
−0.4 pp
−7.9 pp
−6.9 pp
−9.4 pp
−6.9 pp
−2.8 pp
+1.5 pp
+6.5 pp
+4.2 pp
+2.1 pp
+1.0 pp
+3.0 pp
+1.0 pp
+2.0 pp
+1.0 pp
−1.0 pp
+2.0 pp
+3.0 pp
+6.0 pp
+4.0 pp
TTK Healthcare Ltd · TTKHLTCARE⚠ unverified
+5.2 pp
−3.9 pp
−1.3 pp
−3.9 pp
−2.7 pp
+0.6 pp
−0.3 pp
+5.0 pp
+3.0 pp
+2.6 pp
−2.0 pp
−1.0 pp
−2.0 pp
−1.0 pp
+1.0 pp
−1.0 pp
−2.0 pp
−1.0 pp
−1.0 pp
−1.0 pp
Unichem Laboratories Ltd · UNICHEMLAB
−4.4 pp
−7.2 pp
−9.6 pp
+11.6 pp
+0.3 pp
−7.8 pp
−13.6 pp
−14.5 pp
+7.3 pp
+7.6 pp
+21.0 pp
+2.0 pp
+1.0 pp
+9.0 pp
+9.0 pp
+8.0 pp
−4.0 pp
0.0 pp
−7.0 pp
−6.0 pp
03 · compare level, then change
Profit Scale & Acceleration
Sun Pharma Advanced Research Company Ltd has the highest Net profit among the 10 Pharma - Others companies compared here, at ₹1,553 crore. Unichem Laboratories Ltd is next at ₹253 crore. JOJO Ltd has the highest Profit growth at the 100% top of the scoring scale, so level and change sit with different companies.
What the numbers say: Sun Pharma Advanced Research Company Ltd leads with ₹1,553 crore of TTM profit, 513.8% above Unichem Laboratories Ltd. JOJO Ltd shows ≥100% on the scoring scale growth from a ₹6 crore profit base. Compare the size of the base and persistence before ranking acceleration above profit scale.
LeaderSun Pharma Advanced Research Company Ltd · ₹1,553 crore
Gap513.8% versus #2 · Unichem Laboratories Ltd
Persistence0/1 recent comparable periods
Coverage10/10 companies · 145 observations
Investor read: Sun Pharma Advanced Research Company Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current profit growth signal.
Net profit is the residual after operating costs, interest and tax. Growth off a loss or near-zero base is excluded from the fastest-grower rank.
Net profitlargest
1Sun Pharma Advanced Research Company Ltd SPARC₹1.6K Cr
2Unichem Laboratories Ltd UNICHEMLAB₹253 Cr
3Remus Pharmaceuticals Ltd REMUS⚠ unverified₹87 Cr
4Syncom Formulations (India) Ltd SYNCOMF⚠ unverified₹77 Cr
5TTK Healthcare Ltd TTKHLTCARE⚠ unverified₹66 Cr
Profit growthfastest growers
1JOJO Ltd 531910100%
2Remus Pharmaceuticals Ltd REMUS⚠ unverified100%
3Shukra Pharmaceuticals Ltd SHUKRAPHAR100%
4Unichem Laboratories Ltd UNICHEMLAB83%
5Syncom Formulations (India) Ltd SYNCOMF⚠ unverified54%
Net profit · company comparison
10/10 level · 8/10 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Net profit | Profit growth | Reported |
|---|---|---|---|
| Sun Pharma Advanced Research Company Ltd SPARC | ₹1.8K Cr | -1,100% | Mar 2026 |
| Syncom Formulations (India) Ltd SYNCOMF⚠ unverified | ₹25 Cr | 39% | Mar 2026 |
| Remus Pharmaceuticals Ltd REMUS⚠ unverified | ₹25 Cr | 19% | Mar 2026 |
| TTK Healthcare Ltd TTKHLTCARE⚠ unverified | ₹22 Cr | 38% | Mar 2026 |
| Shukra Pharmaceuticals Ltd SHUKRAPHAR | ₹20 Cr | 567% | Dec 2025 |
| Jenburkt Pharmaceuticals Ltd 524731 | ₹11 Cr | 22% | Mar 2026 |
| Unichem Laboratories Ltd UNICHEMLAB | ₹11 Cr | -79% | Mar 2026 |
| JOJO Ltd 531910 | ₹5 Cr | 7,883% | Mar 2026 |
| Madhuveer Com 18 Network Ltd MADHUVEER | ₹1 Cr | 3.0% | Dec 2025 |
| Panacea Biotec Ltd PANACEABIO | ₹-1 Cr | -12% | Mar 2026 |
Full 20-quarter history · every available company
Net profit · reported quarter history
Jenburkt Pharmaceuticals Ltd · 524731
—
—
—
—
—
—
—
₹6 Cr
₹5 Cr
₹7 Cr
₹5 Cr
₹8 Cr
₹7 Cr
₹10 Cr
₹7 Cr
₹9 Cr
₹8 Cr
₹10 Cr
₹6 Cr
₹11 Cr
JOJO Ltd · 531910
—
—
—
—
—
₹0 Cr
₹0 Cr
₹-0 Cr
₹0 Cr
₹-0 Cr
₹0 Cr
₹3 Cr
₹-2 Cr
₹-1 Cr
₹1 Cr
₹0 Cr
₹-1 Cr
₹0 Cr
₹1 Cr
₹5 Cr
Madhuveer Com 18 Network Ltd · MADHUVEER
—
—
—
—
—
—
₹0 Cr
₹-0 Cr
₹0 Cr
₹-0 Cr
₹0 Cr
₹3 Cr
₹-2 Cr
₹-1 Cr
₹1 Cr
₹0 Cr
₹-1 Cr
₹0 Cr
₹1 Cr
—
Panacea Biotec Ltd · PANACEABIO
₹-57 Cr
₹-53 Cr
₹-49 Cr
₹1.2K Cr
₹-56 Cr
₹16 Cr
₹19 Cr
₹-13 Cr
₹11 Cr
₹-8 Cr
₹-2 Cr
₹-2 Cr
₹-16 Cr
₹5 Cr
₹4 Cr
₹-2 Cr
₹4 Cr
₹-14 Cr
₹4 Cr
₹-1 Cr
Remus Pharmaceuticals Ltd · REMUS⚠ unverified
—
—
—
₹1 Cr
—
₹4 Cr
—
₹4 Cr
—
₹6 Cr
—
₹19 Cr
—
₹19 Cr
—
₹21 Cr
—
₹22 Cr
—
₹25 Cr
Shukra Pharmaceuticals Ltd · SHUKRAPHAR
—
—
—
—
—
—
₹0 Cr
₹4 Cr
₹0 Cr
₹5 Cr
₹9 Cr
₹4 Cr
₹0 Cr
₹1 Cr
₹3 Cr
₹5 Cr
₹1 Cr
₹2 Cr
₹20 Cr
—
Sun Pharma Advanced Research Company Ltd · SPARC
₹-61 Cr
₹-55 Cr
₹-16 Cr
₹-71 Cr
₹-82 Cr
₹-68 Cr
₹10 Cr
₹-82 Cr
₹-95 Cr
₹-86 Cr
₹-100 Cr
₹-106 Cr
₹-96 Cr
₹-107 Cr
₹-80 Cr
₹-60 Cr
₹-52 Cr
₹-76 Cr
₹-80 Cr
₹1.8K Cr
Syncom Formulations (India) Ltd · SYNCOMF⚠ unverified
—
—
—
—
—
—
₹4 Cr
₹8 Cr
₹4 Cr
₹7 Cr
₹7 Cr
₹7 Cr
₹8 Cr
₹11 Cr
₹13 Cr
₹18 Cr
₹16 Cr
₹17 Cr
₹19 Cr
₹25 Cr
TTK Healthcare Ltd · TTKHLTCARE⚠ unverified
—
—
—
—
—
—
₹12 Cr
₹17 Cr
₹16 Cr
₹16 Cr
₹13 Cr
₹18 Cr
₹32 Cr
₹17 Cr
₹17 Cr
₹16 Cr
₹13 Cr
₹20 Cr
₹11 Cr
₹22 Cr
Unichem Laboratories Ltd · UNICHEMLAB
—
—
—
—
—
—
₹-64 Cr
₹-44 Cr
₹-1 Cr
₹-24 Cr
₹73 Cr
₹-129 Cr
₹2 Cr
₹25 Cr
₹58 Cr
₹53 Cr
₹-10 Cr
₹-12 Cr
₹264 Cr
₹11 Cr
Profit growth · reported quarter history
Jenburkt Pharmaceuticals Ltd · 524731
—
—
—
—
—
—
—
—
—
—
—
33%
40%
43%
40%
13%
14%
0.0%
-14%
22%
JOJO Ltd · 531910
—
—
—
—
—
—
—
—
—
—
100%
—
—
—
4,850%
-98%
—
—
3.0%
7,883%
Madhuveer Com 18 Network Ltd · MADHUVEER
—
—
—
—
—
—
—
—
—
—
100%
—
—
—
4,850%
-98%
—
—
3.0%
—
Panacea Biotec Ltd · PANACEABIO
—
—
—
—
—
—
—
-101%
—
-152%
-111%
—
-245%
—
—
—
—
-397%
-12%
—
Remus Pharmaceuticals Ltd · REMUS⚠ unverified
—
—
—
—
—
—
—
300%
—
50%
—
375%
—
217%
—
11%
—
16%
—
19%
Shukra Pharmaceuticals Ltd · SHUKRAPHAR
—
—
—
—
—
—
—
—
—
—
—
0.0%
—
-80%
-67%
25%
—
100%
567%
—
Sun Pharma Advanced Research Company Ltd · SPARC
—
—
—
—
—
—
—
—
—
—
-1,100%
—
—
—
—
—
—
—
—
—
Syncom Formulations (India) Ltd · SYNCOMF⚠ unverified
—
—
—
—
—
—
—
—
—
—
75%
-13%
100%
57%
86%
157%
100%
55%
46%
39%
TTK Healthcare Ltd · TTKHLTCARE⚠ unverified
—
—
—
—
—
—
—
—
—
—
8.3%
5.9%
100%
6.3%
31%
-11%
-59%
18%
-35%
38%
Unichem Laboratories Ltd · UNICHEMLAB
—
—
—
—
—
—
—
—
—
—
—
—
—
—
-21%
—
-600%
-148%
355%
-79%
04 · compare level, then change
Capacity Spending & Returns On It
Remus Pharmaceuticals Ltd has the highest CAPEX among the 10 Pharma - Others companies compared here, at ₹11 crore. The same company also holds the highest CAPEX intensity, at 2.4%. 1 of 10 companies report a comparable reading, the latest through Mar 2026. Its CAPEX series carries 4 reported observations across the 20-quarter window.
What the numbers say: Remus Pharmaceuticals Ltd reports ₹11 crore of CAPEX; Remus Pharmaceuticals Ltd has the highest covered intensity at 2.4%. Coverage is only 1 of 10 companies and 4 reported observations, so this is partial evidence—not a complete sector rank.
LeaderRemus Pharmaceuticals Ltd · ₹11 crore
GapNot enough peers
Persistence4/4 recent comparable periods
Coverage1/10 companies · 4 observations
Investor read: Use the CAPEX rank as a diligence queue. Verify commissioning, utilization, cash conversion and post-investment ROCE before treating spend as value creation.
This conclusion weakens if: CAPEX rises without higher utilization, operating cash flow or incremental returns.
CAPEX is cash spent on property, plant, equipment and other reported capital assets. CAPEX intensity divides that spend by revenue; high intensity is a reinvestment signal, not proof that the reinvestment will earn attractive returns.
CAPEXlargest spenders
1Remus Pharmaceuticals Ltd REMUS⚠ unverified₹11 Cr
CAPEX intensityhighest reinvestment intensity
1Remus Pharmaceuticals Ltd REMUS⚠ unverified2.4%
Capital expenditure · company comparison
1/10 level · 1/10 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
Withheld from this chart: Unichem Laboratories Ltd (UNICHEMLAB) — its two data sources disagree by up to 338% on reported income across 14 comparable periods, so its derived ratios are withheld. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | CAPEX | CAPEX intensity | Reported |
|---|---|---|---|
| Remus Pharmaceuticals Ltd REMUS⚠ unverified | ₹11 Cr | 2.4% | Mar 2026 |
Full 20-quarter history · every available company
CAPEX · reported quarter history
Remus Pharmaceuticals Ltd · REMUS⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
—
₹3 Cr
—
₹1 Cr
—
₹3 Cr
—
₹11 Cr
CAPEX intensity · reported quarter history
Remus Pharmaceuticals Ltd · REMUS⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
—
1.1%
—
0.3%
—
0.8%
—
2.4%
Annual capital allocation · 10-year view
10/10 capacity base · 10/10 OCF · 10/10 CAPEX · 10/10 FCF
Capacity base is net fixed assets plus capital work in progress, straight off the reported balance sheet. It is not cash spent, so it answers a narrower question than CAPEX — but it is reported for companies whose cash-flow CAPEX is not published, which is why it leads here. Missing years remain blank; annual values are never relabelled as quarters.
Full annual capacity base, operating cash flow, CAPEX and free cash flow history
Capacity base · net fixed assets + CWIP · fiscal-year history
Jenburkt Pharmaceuticals Ltd · 524731
₹11 Cr
₹10 Cr
₹11 Cr
₹12 Cr
₹11 Cr
₹11 Cr
₹11 Cr
₹11 Cr
₹55 Cr
₹65 Cr
JOJO Ltd · 531910
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹14 Cr
₹20 Cr
₹32 Cr
Madhuveer Com 18 Network Ltd · MADHUVEER
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹14 Cr
₹20 Cr
—
Panacea Biotec Ltd · PANACEABIO
₹1.0K Cr
₹989 Cr
₹829 Cr
₹681 Cr
₹643 Cr
₹639 Cr
₹642 Cr
₹684 Cr
₹695 Cr
₹720 Cr
Remus Pharmaceuticals Ltd · REMUS⚠ unverified
—
—
—
₹0 Cr
₹0 Cr
₹0 Cr
₹3 Cr
₹14 Cr
₹16 Cr
₹26 Cr
Shukra Pharmaceuticals Ltd · SHUKRAPHAR
₹12 Cr
₹16 Cr
₹18 Cr
₹19 Cr
₹20 Cr
₹20 Cr
₹22 Cr
₹22 Cr
₹21 Cr
—
Sun Pharma Advanced Research Company Ltd · SPARC
—
—
—
—
—
—
₹133 Cr
₹152 Cr
₹153 Cr
₹157 Cr
Syncom Formulations (India) Ltd · SYNCOMF⚠ unverified
₹55 Cr
—
—
—
—
₹100 Cr
₹117 Cr
₹120 Cr
₹125 Cr
₹184 Cr
TTK Healthcare Ltd · TTKHLTCARE⚠ unverified
₹99 Cr
₹111 Cr
₹100 Cr
₹98 Cr
₹85 Cr
₹80 Cr
₹74 Cr
₹76 Cr
₹81 Cr
₹74 Cr
Unichem Laboratories Ltd · UNICHEMLAB
₹741 Cr
₹816 Cr
₹902 Cr
₹1.2K Cr
₹1.5K Cr
₹1.5K Cr
₹1.4K Cr
₹1.4K Cr
₹1.3K Cr
₹1.3K Cr
Operating cash flow · fiscal-year history
Jenburkt Pharmaceuticals Ltd · 524731
₹10 Cr
₹16 Cr
₹13 Cr
₹15 Cr
₹19 Cr
₹9 Cr
₹17 Cr
₹8 Cr
₹28 Cr
₹27 Cr
JOJO Ltd · 531910
₹6 Cr
₹0 Cr
₹0 Cr
₹-0 Cr
₹0 Cr
₹-0 Cr
₹-0 Cr
₹-1 Cr
₹-13 Cr
₹11 Cr
Madhuveer Com 18 Network Ltd · MADHUVEER
₹6 Cr
₹0 Cr
₹0 Cr
₹-0 Cr
₹0 Cr
₹-0 Cr
₹-0 Cr
₹-1 Cr
₹-13 Cr
—
Panacea Biotec Ltd · PANACEABIO
₹131 Cr
₹118 Cr
₹105 Cr
₹-30 Cr
₹107 Cr
₹-108 Cr
₹-422 Cr
₹0 Cr
₹-27 Cr
₹17 Cr
Remus Pharmaceuticals Ltd · REMUS⚠ unverified
—
—
—
₹1 Cr
₹0 Cr
₹5 Cr
₹5 Cr
₹4 Cr
₹7 Cr
₹18 Cr
Shukra Pharmaceuticals Ltd · SHUKRAPHAR
₹0 Cr
₹1 Cr
₹0 Cr
₹1 Cr
₹1 Cr
₹8 Cr
₹3 Cr
₹-5 Cr
₹8 Cr
—
Sun Pharma Advanced Research Company Ltd · SPARC
—
—
—
—
—
₹-208 Cr
₹-69 Cr
₹-429 Cr
₹-360 Cr
₹-239 Cr
Syncom Formulations (India) Ltd · SYNCOMF⚠ unverified
₹14 Cr
—
—
—
—
₹16 Cr
₹11 Cr
₹-6 Cr
₹23 Cr
₹58 Cr
TTK Healthcare Ltd · TTKHLTCARE⚠ unverified
₹18 Cr
₹25 Cr
₹17 Cr
₹20 Cr
₹96 Cr
₹45 Cr
₹-25 Cr
₹-5 Cr
₹-4 Cr
₹-21 Cr
Unichem Laboratories Ltd · UNICHEMLAB
₹68 Cr
₹-112 Cr
₹-328 Cr
₹20 Cr
₹33 Cr
₹-260 Cr
₹-85 Cr
₹14 Cr
₹-7 Cr
₹4 Cr
CAPEX · reported cash flow · fiscal-year history
Jenburkt Pharmaceuticals Ltd · 524731
₹1 Cr
₹1 Cr
₹2 Cr
₹3 Cr
₹1 Cr
₹2 Cr
₹2 Cr
₹2 Cr
₹47 Cr
₹13 Cr
JOJO Ltd · 531910
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹-0 Cr
₹15 Cr
₹7 Cr
₹14 Cr
Madhuveer Com 18 Network Ltd · MADHUVEER
—
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹0 Cr
₹-0 Cr
₹15 Cr
₹7 Cr
—
Panacea Biotec Ltd · PANACEABIO
₹-133 Cr
₹15 Cr
₹-106 Cr
₹-105 Cr
₹8 Cr
₹40 Cr
₹42 Cr
₹79 Cr
₹46 Cr
₹58 Cr
Remus Pharmaceuticals Ltd · REMUS⚠ unverified
—
—
—
—
₹0 Cr
₹0 Cr
₹3 Cr
₹12 Cr
₹4 Cr
₹13 Cr
Shukra Pharmaceuticals Ltd · SHUKRAPHAR
₹0 Cr
₹5 Cr
₹3 Cr
₹2 Cr
₹2 Cr
₹2 Cr
₹4 Cr
₹2 Cr
₹2 Cr
—
Sun Pharma Advanced Research Company Ltd · SPARC
—
—
—
—
—
—
—
₹32 Cr
₹13 Cr
₹14 Cr
Syncom Formulations (India) Ltd · SYNCOMF⚠ unverified
₹7 Cr
—
—
—
—
—
₹22 Cr
₹8 Cr
₹10 Cr
₹66 Cr
TTK Healthcare Ltd · TTKHLTCARE⚠ unverified
₹4 Cr
₹27 Cr
₹4 Cr
₹12 Cr
₹0 Cr
₹8 Cr
₹7 Cr
₹15 Cr
₹13 Cr
₹2 Cr
Unichem Laboratories Ltd · UNICHEMLAB
₹145 Cr
₹126 Cr
₹153 Cr
₹380 Cr
₹336 Cr
₹123 Cr
₹33 Cr
₹94 Cr
₹81 Cr
₹107 Cr
Free cash flow · fiscal-year history
Jenburkt Pharmaceuticals Ltd · 524731
₹9 Cr
₹15 Cr
₹11 Cr
₹12 Cr
₹18 Cr
₹7 Cr
₹15 Cr
₹6 Cr
₹-19 Cr
₹14 Cr
JOJO Ltd · 531910
₹6 Cr
₹0 Cr
₹0 Cr
₹-0 Cr
₹0 Cr
₹-0 Cr
₹-0 Cr
₹-16 Cr
₹-20 Cr
₹-3 Cr
Madhuveer Com 18 Network Ltd · MADHUVEER
—
₹0 Cr
₹0 Cr
₹-0 Cr
₹0 Cr
₹-0 Cr
₹-0 Cr
₹-16 Cr
₹-20 Cr
—
Panacea Biotec Ltd · PANACEABIO
₹264 Cr
₹103 Cr
₹211 Cr
₹75 Cr
₹99 Cr
₹-148 Cr
₹-464 Cr
₹-79 Cr
₹-73 Cr
₹-41 Cr
Remus Pharmaceuticals Ltd · REMUS⚠ unverified
—
—
—
—
₹0 Cr
₹5 Cr
₹2 Cr
₹-8 Cr
₹3 Cr
₹5 Cr
Shukra Pharmaceuticals Ltd · SHUKRAPHAR
₹0 Cr
₹-4 Cr
₹-3 Cr
₹-1 Cr
₹-1 Cr
₹6 Cr
₹-1 Cr
₹-7 Cr
₹6 Cr
—
Sun Pharma Advanced Research Company Ltd · SPARC
—
—
—
—
—
—
—
₹-461 Cr
₹-373 Cr
₹-253 Cr
Syncom Formulations (India) Ltd · SYNCOMF⚠ unverified
₹7 Cr
—
—
—
—
—
₹-11 Cr
₹-14 Cr
₹13 Cr
₹-8 Cr
TTK Healthcare Ltd · TTKHLTCARE⚠ unverified
₹14 Cr
₹-2 Cr
₹13 Cr
₹8 Cr
₹96 Cr
₹37 Cr
₹-32 Cr
₹-20 Cr
₹-17 Cr
₹-23 Cr
Unichem Laboratories Ltd · UNICHEMLAB
₹-77 Cr
₹-238 Cr
₹-481 Cr
₹-360 Cr
₹-303 Cr
₹-383 Cr
₹-118 Cr
₹-80 Cr
₹-88 Cr
₹-103 Cr
05 · compare level, then change
Debt Load & Balance-Sheet Headroom
Syncom Formulations (India) Ltd has the lowest Gross debt among the 10 Pharma - Others companies compared here, at ₹1 crore. Jenburkt Pharmaceuticals Ltd is next at ₹2 crore. TTK Healthcare Ltd has the lowest Net debt at ₹912 crore net cash, so level and change sit with different companies.
What the numbers say: TTK Healthcare Ltd has the clearest covered balance-sheet capacity with ₹912 crore net cash and gross debt of ₹24 crore. Absolute debt alone does not identify the strongest balance sheet because company scale differs; net debt and debt-to-equity carry more information.
LeaderSyncom Formulations (India) Ltd · ₹1 crore
Gap50% versus #2 · Jenburkt Pharmaceuticals Ltd
Persistence8/8 recent comparable periods
Coverage10/10 companies · 114 observations
Investor read: Prioritize net-cash capacity and leverage relative to operating scale, not the smallest absolute rupee debt.
This conclusion weakens if: Net debt rises faster than revenue and profit for two consecutive reported periods.
Gross debt shows contractual borrowings. Net debt subtracts reported cash; a negative value means net cash. Lower debt can create capacity, but should be read against the scale and capital intensity of the business.
Gross debtlowest gross debt
1Syncom Formulations (India) Ltd SYNCOMF⚠ unverified₹1 Cr
2Jenburkt Pharmaceuticals Ltd 524731₹2 Cr
3Madhuveer Com 18 Network Ltd MADHUVEER₹2 Cr
4JOJO Ltd 531910₹3 Cr
5Shukra Pharmaceuticals Ltd SHUKRAPHAR₹4 Cr
Net debtlowest net debt
1TTK Healthcare Ltd TTKHLTCARE⚠ unverified₹-912 Cr
2Syncom Formulations (India) Ltd SYNCOMF⚠ unverified₹-112 Cr
3Panacea Biotec Ltd PANACEABIO₹-111 Cr
4Remus Pharmaceuticals Ltd REMUS⚠ unverified₹-28 Cr
5Sun Pharma Advanced Research Company Ltd SPARC₹558 Cr
Debt and balance-sheet capacity · company comparison
10/10 level · 5/10 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Gross debt | Net debt | Reported |
|---|---|---|---|
| Sun Pharma Advanced Research Company Ltd SPARC | ₹559 Cr | ₹558 Cr | Mar 2026 |
| Unichem Laboratories Ltd UNICHEMLAB | ₹500 Cr | — | Mar 2026 |
| Remus Pharmaceuticals Ltd REMUS⚠ unverified | ₹27 Cr | ₹-28 Cr | Mar 2026 |
| Panacea Biotec Ltd PANACEABIO | ₹24 Cr | ₹-111 Cr | Mar 2026 |
| TTK Healthcare Ltd TTKHLTCARE⚠ unverified | ₹24 Cr | ₹-912 Cr | Mar 2026 |
| Shukra Pharmaceuticals Ltd SHUKRAPHAR | ₹4 Cr | — | Dec 2025 |
| JOJO Ltd 531910 | ₹3 Cr | — | Mar 2026 |
| Madhuveer Com 18 Network Ltd MADHUVEER | ₹2 Cr | — | Dec 2025 |
| Jenburkt Pharmaceuticals Ltd 524731 | ₹2 Cr | — | Mar 2026 |
| Syncom Formulations (India) Ltd SYNCOMF⚠ unverified | ₹1 Cr | ₹-112 Cr | Mar 2026 |
Full 20-quarter history · every available company
Gross debt · reported quarter history
Jenburkt Pharmaceuticals Ltd · 524731
—
—
—
₹7 Cr
—
—
—
₹3 Cr
—
—
—
₹0 Cr
—
—
—
₹4 Cr
—
—
—
₹2 Cr
JOJO Ltd · 531910
—
—
—
₹0 Cr
—
—
—
₹0 Cr
—
—
—
₹7 Cr
—
—
—
₹7 Cr
—
₹2 Cr
—
₹3 Cr
Madhuveer Com 18 Network Ltd · MADHUVEER
—
—
—
₹0 Cr
—
—
—
₹0 Cr
—
—
—
₹7 Cr
—
—
—
₹7 Cr
—
₹2 Cr
—
—
Panacea Biotec Ltd · PANACEABIO
₹851 Cr
₹827 Cr
₹827 Cr
₹34 Cr
₹34 Cr
₹32 Cr
₹32 Cr
₹20 Cr
₹20 Cr
₹21 Cr
₹21 Cr
₹21 Cr
₹21 Cr
₹22 Cr
₹22 Cr
₹22 Cr
₹22 Cr
₹23 Cr
₹23 Cr
₹24 Cr
Remus Pharmaceuticals Ltd · REMUS⚠ unverified
—
—
—
₹0 Cr
—
—
—
₹8 Cr
—
—
—
₹14 Cr
—
₹21 Cr
—
₹23 Cr
—
₹16 Cr
—
₹27 Cr
Shukra Pharmaceuticals Ltd · SHUKRAPHAR
—
—
—
₹3 Cr
—
—
—
₹5 Cr
—
—
—
₹3 Cr
—
—
—
₹4 Cr
—
₹4 Cr
—
—
Sun Pharma Advanced Research Company Ltd · SPARC
₹197 Cr
₹155 Cr
₹155 Cr
₹79 Cr
₹79 Cr
₹193 Cr
₹193 Cr
₹16 Cr
₹16 Cr
₹14 Cr
₹14 Cr
₹61 Cr
₹61 Cr
₹101 Cr
₹101 Cr
₹269 Cr
₹269 Cr
₹417 Cr
₹417 Cr
₹559 Cr
Syncom Formulations (India) Ltd · SYNCOMF⚠ unverified
₹62 Cr
₹64 Cr
₹64 Cr
₹58 Cr
₹58 Cr
₹96 Cr
₹96 Cr
₹83 Cr
₹83 Cr
₹80 Cr
₹80 Cr
₹72 Cr
₹72 Cr
₹14 Cr
₹14 Cr
₹5 Cr
₹5 Cr
₹1 Cr
₹1 Cr
₹1 Cr
TTK Healthcare Ltd · TTKHLTCARE⚠ unverified
₹19 Cr
₹6 Cr
₹6 Cr
₹22 Cr
₹22 Cr
₹24 Cr
₹24 Cr
₹27 Cr
₹27 Cr
₹25 Cr
₹25 Cr
₹23 Cr
₹23 Cr
₹31 Cr
₹31 Cr
₹24 Cr
₹24 Cr
₹27 Cr
₹27 Cr
₹24 Cr
Unichem Laboratories Ltd · UNICHEMLAB
—
—
—
₹349 Cr
—
—
—
₹314 Cr
—
—
—
₹248 Cr
—
—
—
₹460 Cr
—
₹502 Cr
—
₹500 Cr
Net debt · reported quarter history
Panacea Biotec Ltd · PANACEABIO
₹715 Cr
₹686 Cr
₹686 Cr
₹-518 Cr
₹-554 Cr
₹-268 Cr
₹-268 Cr
₹-193 Cr
₹-219 Cr
₹-163 Cr
₹-163 Cr
₹-130 Cr
₹-159 Cr
₹-155 Cr
₹-155 Cr
₹-107 Cr
₹-88 Cr
₹-105 Cr
₹-105 Cr
₹-111 Cr
Remus Pharmaceuticals Ltd · REMUS⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
₹-11 Cr
—
₹-25 Cr
—
₹-4 Cr
—
₹-16 Cr
—
₹-28 Cr
Sun Pharma Advanced Research Company Ltd · SPARC
₹181 Cr
₹72 Cr
₹72 Cr
₹66 Cr
₹66 Cr
₹189 Cr
₹189 Cr
₹-386 Cr
₹-386 Cr
₹-352 Cr
₹-352 Cr
₹-96 Cr
₹-96 Cr
₹95 Cr
₹95 Cr
₹267 Cr
₹267 Cr
₹416 Cr
₹416 Cr
₹558 Cr
Syncom Formulations (India) Ltd · SYNCOMF⚠ unverified
₹-12 Cr
₹-32 Cr
₹-32 Cr
₹18 Cr
₹16 Cr
₹28 Cr
₹28 Cr
₹12 Cr
₹12 Cr
₹19 Cr
₹19 Cr
₹-60 Cr
₹-60 Cr
₹-78 Cr
₹-78 Cr
₹-85 Cr
₹-85 Cr
₹-144 Cr
₹-144 Cr
₹-112 Cr
TTK Healthcare Ltd · TTKHLTCARE⚠ unverified
₹-208 Cr
₹-242 Cr
₹-242 Cr
₹-251 Cr
₹-251 Cr
₹-928 Cr
₹-928 Cr
₹-820 Cr
₹-820 Cr
₹-820 Cr
₹-820 Cr
₹-822 Cr
₹-822 Cr
₹-762 Cr
₹-762 Cr
₹-831 Cr
₹-831 Cr
₹-574 Cr
₹-574 Cr
₹-912 Cr
06 · compare level, then change
Return On Capital Employed
Sun Pharma Advanced Research Company Ltd has the highest ROCE among the 10 Pharma - Others companies compared here, at 164%. Jenburkt Pharmaceuticals Ltd is next at 27.2%. JOJO Ltd has the highest ROCE change at +18.1 percentage points, so level and change sit with different companies. 10 of 10 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: Sun Pharma Advanced Research Company Ltd leads ROCE at 164%, 136.8 percentage points above Jenburkt Pharmaceuticals Ltd. JOJO Ltd has the strongest latest improvement at +18.1 percentage points. Read the leader beside the density of its reported history: a sparse high return is a candidate; a repeated high return is evidence of durability.
LeaderSun Pharma Advanced Research Company Ltd · 164%
Gap502.9% versus #2 · Jenburkt Pharmaceuticals Ltd
Persistence2/8 recent comparable periods
Coverage10/10 companies · 64 observations
Investor read: Sun Pharma Advanced Research Company Ltd sets the level benchmark; use the change leader as an inflection watch only after another comparable report confirms it.
This conclusion weakens if: The next two comparable reports reverse the current roce change signal.
ROCE asks how much operating return the business earns on the capital employed. Direction matters, but a single exceptional year should not be mistaken for durability.
ROCEhighest
1Sun Pharma Advanced Research Company Ltd SPARC164%
2Jenburkt Pharmaceuticals Ltd 52473127%
3Syncom Formulations (India) Ltd SYNCOMF⚠ unverified27%
4Shukra Pharmaceuticals Ltd SHUKRAPHAR22%
5JOJO Ltd 53191017%
ROCE changefastest improvers
1JOJO Ltd 531910+18.1 pp
2Syncom Formulations (India) Ltd SYNCOMF⚠ unverified+2.5 pp
3Panacea Biotec Ltd PANACEABIO+1.2 pp
4Jenburkt Pharmaceuticals Ltd 5247310.0 pp
5TTK Healthcare Ltd TTKHLTCARE⚠ unverified−0.3 pp
Return on capital · company comparison
10/10 level · 10/10 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
Withheld from this chart: Unichem Laboratories Ltd (UNICHEMLAB) — its two data sources disagree by up to 338% on reported income across 14 comparable periods, so its derived ratios are withheld. A figure two sources cannot agree on is not drawn — the gap is a decision, not missing data.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | ROCE | ROCE change | Reported |
|---|---|---|---|
| Sun Pharma Advanced Research Company Ltd SPARC | 112% | −750.2 pp | Mar 2026 |
| Syncom Formulations (India) Ltd SYNCOMF⚠ unverified | 17% | +2.5 pp | Mar 2026 |
| Remus Pharmaceuticals Ltd REMUS⚠ unverified | 13% | −1.5 pp | Mar 2026 |
| TTK Healthcare Ltd TTKHLTCARE⚠ unverified | 1.6% | −0.3 pp | Mar 2026 |
| Panacea Biotec Ltd PANACEABIO | -4.1% | +1.2 pp | Mar 2026 |
Full 20-quarter history · every available company
ROCE · reported quarter history
Panacea Biotec Ltd · PANACEABIO
—
-1.5%
—
-4.9%
—
-12%
—
-11%
—
-4.8%
2.7%
-4.5%
-2.7%
-4.2%
-0.7%
-5.3%
2.1%
-7.1%
0.0%
-4.1%
Remus Pharmaceuticals Ltd · REMUS⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
15%
—
31%
—
14%
—
13%
—
13%
Sun Pharma Advanced Research Company Ltd · SPARC
—
-251%
—
-181%
—
625%
—
-34%
—
-61%
-129%
-165%
-86%
-991%
-154%
862%
-195%
150%
-574%
112%
Syncom Formulations (India) Ltd · SYNCOMF⚠ unverified
—
14%
—
7.0%
—
4.3%
—
5.7%
—
7.2%
14%
8.3%
14%
11%
18%
14%
23%
16%
25%
17%
TTK Healthcare Ltd · TTKHLTCARE⚠ unverified
—
8.2%
—
—
—
1.6%
—
1.9%
—
3.1%
9.1%
2.4%
11%
2.1%
11%
1.9%
8.7%
1.2%
7.4%
1.6%
ROCE change · reported quarter history
Panacea Biotec Ltd · PANACEABIO
—
—
—
—
—
−10.9 pp
—
−6.0 pp
—
+7.6 pp
—
+6.4 pp
—
+0.6 pp
−3.4 pp
−0.8 pp
+4.8 pp
−2.9 pp
+0.7 pp
+1.2 pp
Remus Pharmaceuticals Ltd · REMUS⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
−0.4 pp
—
−17.6 pp
—
−1.5 pp
Sun Pharma Advanced Research Company Ltd · SPARC
—
—
—
—
—
+875.8 pp
—
+146.5 pp
—
−686.1 pp
—
−130.3 pp
—
−929.7 pp
−24.6 pp
+1,027.0 pp
−109.0 pp
+1,140.7 pp
−420.2 pp
−750.2 pp
Syncom Formulations (India) Ltd · SYNCOMF⚠ unverified
—
—
—
—
—
−9.8 pp
—
−1.3 pp
—
+2.9 pp
—
+2.6 pp
—
+3.3 pp
+3.7 pp
+5.7 pp
+8.8 pp
+5.1 pp
+7.6 pp
+2.5 pp
TTK Healthcare Ltd · TTKHLTCARE⚠ unverified
—
—
—
—
—
−6.6 pp
—
—
—
+1.5 pp
—
+0.5 pp
—
−1.0 pp
+2.3 pp
−0.5 pp
−2.3 pp
−0.9 pp
−4.0 pp
−0.3 pp
07 · compare level, then change
Valuation Against Growth & Quality
No company in this Pharma - Others comparison has a valuation figure that passes this section's guard, so the Guarded PEG rank is empty. On P/E, Sun Pharma Advanced Research Company Ltd is lowest at 4.48×, across 9 of 10 companies with a usable reading.
What the numbers say: There is not enough comparable evidence to name a reliable guarded peg leader.
LeaderNo comparable leader
GapNot enough peers
PersistenceNot enough history
Coverage0/10 companies · 0 observations
Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.
This conclusion weakens if: The next two comparable reports reverse the current p/e signal.
PEG is shown only when earnings are positive and three-year EPS growth is between 5% and 60%. It is recomputed consistently as the trailing P/E divided by that growth rate — reported earnings, never an expected-earnings multiple. On Indian companies it is shown only where the two data sources reconciled. A missing PEG is more honest than a low-base fiction.
Guarded PEGlowest PEG
—Not enough comparable data—
P/Elowest P/E
1Sun Pharma Advanced Research Company Ltd SPARC4.5
2Jenburkt Pharmaceuticals Ltd 52473113.2
3Syncom Formulations (India) Ltd SYNCOMF⚠ unverified16.1
4TTK Healthcare Ltd TTKHLTCARE⚠ unverified21.6
5Remus Pharmaceuticals Ltd REMUS⚠ unverified22.9
Valuation · company comparison
0/10 level · 9/10 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | Guarded PEG | P/E | Reported |
|---|---|---|---|
| Jenburkt Pharmaceuticals Ltd 524731 | — | 13.8 | Mar 2026 |
| JOJO Ltd 531910 | — | 572.8 | Mar 2026 |
| Sun Pharma Advanced Research Company Ltd SPARC | — | 2.4 | Mar 2026 |
| Unichem Laboratories Ltd UNICHEMLAB | — | 19.0 | Mar 2026 |
| Panacea Biotec Ltd PANACEABIO | — | -337.7 | Mar 2026 |
| Shukra Pharmaceuticals Ltd SHUKRAPHAR | — | 217.6 | Dec 2025 |
| TTK Healthcare Ltd TTKHLTCARE⚠ unverified | — | 15.6 | Mar 2026 |
| Syncom Formulations (India) Ltd SYNCOMF⚠ unverified | — | 15.0 | Mar 2026 |
| Remus Pharmaceuticals Ltd REMUS⚠ unverified | — | 21.6 | Mar 2026 |
| Madhuveer Com 18 Network Ltd MADHUVEER | — | 669.7 | Dec 2025 |
Full 20-quarter history · every available company
No consistent historical series is available for guarded peg.
P/E · reported quarter history
Jenburkt Pharmaceuticals Ltd · 524731
13.6
11.1
10.9
10.8
10.0
10.6
13.3
14.1
13.3
13.1
12.4
12.4
14.8
17.1
17.3
14.2
18.3
14.7
14.4
13.8
JOJO Ltd · 531910
—
—
—
—
—
—
—
—
3,400.0
3,069.0
—
—
—
87.9
190.6
118.3
110.4
—
669.7
572.8
Madhuveer Com 18 Network Ltd · MADHUVEER
—
—
—
—
—
—
—
—
3,400.0
3,069.0
—
—
—
87.9
190.6
118.3
110.4
—
669.7
—
Panacea Biotec Ltd · PANACEABIO
—
—
—
0.8
—
0.7
0.7
—
23.1
—
—
—
—
-123.9
-314.9
—
227.6
—
-296.3
-337.7
Remus Pharmaceuticals Ltd · REMUS⚠ unverified
—
—
—
—
—
—
—
—
—
132.8
—
49.5
—
76.0
—
47.1
—
31.0
—
21.6
Shukra Pharmaceuticals Ltd · SHUKRAPHAR
—
38.0
44.0
36.0
26.0
52.0
23.0
58.5
46.6
38.9
14.8
19.0
25.9
15.7
37.5
115.0
62.1
149.9
217.6
—
Sun Pharma Advanced Research Company Ltd · SPARC
—
—
—
—
—
—
-27.1
—
—
—
—
—
—
—
—
—
—
—
—
2.4
Syncom Formulations (India) Ltd · SYNCOMF⚠ unverified
56.7
49.8
94.0
82.4
57.1
58.4
63.4
32.8
36.1
38.1
60.2
39.9
46.1
73.3
56.7
39.2
36.3
27.4
21.5
15.0
TTK Healthcare Ltd · TTKHLTCARE⚠ unverified
23.1
20.9
41.0
49.1
62.8
79.8
62.9
51.5
2.8
29.3
31.2
32.1
33.1
37.2
31.0
24.5
25.6
24.2
20.8
15.6
Unichem Laboratories Ltd · UNICHEMLAB
66.0
87.8
82.7
—
51.2
129.1
149.3
—
—
—
—
—
—
—
191.4
63.4
30.3
27.0
21.5
19.0
08 · compare level, then change
Enterprise Value & Book Value
Sun Pharma Advanced Research Company Ltd has the lowest EV/EBITDA among the 10 Pharma - Others companies compared here, at 4.56×. TTK Healthcare Ltd is next at 5.1×. TTK Healthcare Ltd has the lowest P/BV at 1.33×, so level and change sit with different companies. 9 of 10 companies report a comparable reading, the latest through Mar 2026.
What the numbers say: Sun Pharma Advanced Research Company Ltd leads ev/ebitda at 4.56×; TTK Healthcare Ltd leads p/bv at 1.33×.
LeaderSun Pharma Advanced Research Company Ltd · 4.56×
Gap10.6% versus #2 · TTK Healthcare Ltd
Persistence3/8 recent comparable periods
Coverage9/10 companies · 148 observations
Investor read: Treat valuation as permission to investigate, never as a standalone reason to buy.
This conclusion weakens if: The next two comparable reports reverse the current p/bv signal.
EV/EBITDA includes debt in enterprise value and is useful across different capital structures. P/BV prices the company against its own book. Both are market multiples on reported figures, not intrinsic-value estimates and not forecasts.
EV/EBITDAlowest EV/EBITDA
1Sun Pharma Advanced Research Company Ltd SPARC4.6
2TTK Healthcare Ltd TTKHLTCARE⚠ unverified5.1
3Unichem Laboratories Ltd UNICHEMLAB8.7
4Jenburkt Pharmaceuticals Ltd 5247319.1
5Syncom Formulations (India) Ltd SYNCOMF⚠ unverified10.6
P/BVlowest P/BV
1TTK Healthcare Ltd TTKHLTCARE⚠ unverified1.3
2Unichem Laboratories Ltd UNICHEMLAB1.4
3Remus Pharmaceuticals Ltd REMUS⚠ unverified2.4
4Jenburkt Pharmaceuticals Ltd 5247312.5
5Syncom Formulations (India) Ltd SYNCOMF⚠ unverified3.0
Enterprise and book valuation · company comparison
9/10 level · 10/10 change
Solid lines show level; dotted lines show change when “Both” is selected. Missing reports break the line rather than being invented.
All-company data · latest reported quarter
Each figure is the company’s latest single reported quarter. The rankings above use trailing-twelve-month or current-market values, so a company can legitimately show a different number in each.
| Company | EV/EBITDA | P/BV | Reported |
|---|---|---|---|
| Madhuveer Com 18 Network Ltd MADHUVEER | 1,387.0 | 13.5 | Dec 2025 |
| Panacea Biotec Ltd PANACEABIO | 254.1 | 2.4 | Mar 2026 |
| JOJO Ltd 531910 | 120.4 | 11.6 | Mar 2026 |
| Shukra Pharmaceuticals Ltd SHUKRAPHAR | 76.3 | 34.1 | Dec 2025 |
| Remus Pharmaceuticals Ltd REMUS⚠ unverified | 12.8 | 2.4 | Mar 2026 |
| Syncom Formulations (India) Ltd SYNCOMF⚠ unverified | 10.6 | 2.7 | Mar 2026 |
| Jenburkt Pharmaceuticals Ltd 524731 | 9.1 | 2.4 | Mar 2026 |
| Unichem Laboratories Ltd UNICHEMLAB | 8.7 | 0.8 | Mar 2026 |
| TTK Healthcare Ltd TTKHLTCARE⚠ unverified | 5.1 | 1.0 | Mar 2026 |
| Sun Pharma Advanced Research Company Ltd SPARC | — | -11.4 | Mar 2026 |
Full 20-quarter history · every available company
EV/EBITDA · reported quarter history
Jenburkt Pharmaceuticals Ltd · 524731
7.0
5.9
6.2
6.2
5.3
6.0
7.8
7.7
7.8
7.3
6.9
7.0
8.8
9.8
10.3
8.1
12.0
9.6
9.4
9.1
JOJO Ltd · 531910
—
102.5
—
16.8
85.2
53.4
43.8
315.2
1,605.0
1,727.5
—
—
73.0
97.9
200.6
98.6
680.1
481.1
1,387.0
120.4
Madhuveer Com 18 Network Ltd · MADHUVEER
—
102.5
—
16.8
85.2
53.4
43.8
315.2
1,605.0
1,727.5
—
—
73.0
97.9
200.6
98.6
680.1
481.1
1,387.0
—
Panacea Biotec Ltd · PANACEABIO
34.9
38.0
58.5
61.1
52.7
—
—
—
—
47.8
89.0
59.6
107.4
107.8
212.4
145.2
175.5
254.1
—
—
Remus Pharmaceuticals Ltd · REMUS⚠ unverified
—
—
—
—
—
—
—
—
—
83.1
—
35.6
—
49.9
—
29.1
—
18.1
—
12.8
Shukra Pharmaceuticals Ltd · SHUKRAPHAR
13.6
14.6
15.9
14.1
10.6
13.1
8.6
15.0
31.7
25.8
11.2
16.7
22.0
12.7
27.5
67.5
35.0
76.3
—
—
Syncom Formulations (India) Ltd · SYNCOMF⚠ unverified
32.7
30.2
56.8
51.7
39.2
44.4
47.8
19.2
21.0
23.9
38.0
26.1
28.8
44.4
35.6
26.1
25.4
19.3
15.2
10.6
TTK Healthcare Ltd · TTKHLTCARE⚠ unverified
18.2
14.2
16.5
19.7
21.9
14.3
13.6
20.6
12.1
9.0
11.6
12.3
12.6
16.2
12.4
8.8
9.9
8.4
8.8
5.1
Unichem Laboratories Ltd · UNICHEMLAB
15.9
14.5
20.0
29.8
14.5
24.2
23.4
42.0
52.8
—
66.8
32.1
31.0
35.1
28.4
21.0
14.2
13.0
11.2
8.7
P/BV · reported quarter history
Jenburkt Pharmaceuticals Ltd · 524731
2.8
2.3
2.3
2.3
2.2
2.0
2.4
2.6
2.8
2.5
2.3
2.3
3.1
3.3
3.3
2.8
3.4
2.8
2.6
2.4
JOJO Ltd · 531910
0.4
0.4
0.4
0.6
2.7
1.7
1.5
1.4
4.8
5.1
16.5
11.9
16.4
19.8
28.3
21.8
4.1
10.9
13.5
11.6
Madhuveer Com 18 Network Ltd · MADHUVEER
0.4
0.4
0.4
0.6
2.7
1.7
1.5
1.4
4.8
5.1
16.5
11.9
16.4
19.8
28.3
21.8
4.1
10.9
13.5
—
Panacea Biotec Ltd · PANACEABIO
11.7
-7.7
-3.6
-3.2
-3.5
1.0
1.1
0.8
0.9
1.2
1.2
0.9
1.0
2.1
3.1
3.2
3.0
3.0
3.0
2.4
Remus Pharmaceuticals Ltd · REMUS⚠ unverified
—
—
—
—
—
—
—
—
—
—
—
14.0
—
9.9
—
13.2
—
3.5
—
2.4
Shukra Pharmaceuticals Ltd · SHUKRAPHAR
0.9
1.1
1.2
0.9
1.5
2.7
1.8
2.7
10.8
6.7
3.0
8.0
15.1
5.1
10.0
17.6
6.6
23.9
34.1
—
Sun Pharma Advanced Research Company Ltd · SPARC
-35.8
1,651.3
1,601.2
258.6
182.0
-50.4
-48.4
11.4
13.2
14.8
28.1
36.0
62.1
54.9
52.1
38.2
41.7
-19.7
-12.6
-11.4
Syncom Formulations (India) Ltd · SYNCOMF⚠ unverified
5.3
4.7
8.8
7.7
5.0
5.3
3.5
3.5
4.4
3.1
5.2
3.9
4.6
7.2
6.0
4.9
6.3
4.6
3.6
2.7
TTK Healthcare Ltd · TTKHLTCARE⚠ unverified
3.5
3.2
3.2
3.6
3.5
1.4
1.5
4.5
1.9
1.7
2.1
2.1
2.2
2.4
1.9
1.6
1.8
1.5
1.4
1.0
Unichem Laboratories Ltd · UNICHEMLAB
0.9
0.7
0.7
0.7
0.7
1.1
0.9
0.8
1.0
1.2
1.2
1.4
1.5
1.9
2.1
2.0
1.7
1.4
1.3
0.8
09 · let price answer last
Market action
Shukra Pharmaceuticals Ltd has the strongest one-year price move in Pharma - Others at +92.1%. Sun Pharma Advanced Research Company Ltd leads on Mansfield relative strength against NIFTY at +51.8%. 7 of 10 covered companies are above zero on that measure. Every line covers 313 weekly closes through 2026-07-17.
Every price line is indexed to 100 over the chosen window. Mansfield relative strength compares a price ratio with its own 52-week average; zero separates leadership from lagging.
Price and relative strength
Price is rebased to 100 inside the selected window. Pair ratio rebases each selected company against one chosen denominator.
Before the conclusion · check the blind spots
What can make this comparison misleading?
This Pharma - Others comparison names 7 specific ways its own evidence can mislead, all listed below. All 10 companies here report on comparable dates, so no rank carries a stale marker. 3 draw at least one figure from a second feed with too little overlap to cross-check. 1 has second-feed figures withheld because the two sources disagree.
Keep these limits visible
- A high growth rate can be a low-base artefact. The page keeps level and change separate for that reason.
- A high ROCE can be temporary or flattered by a small capital base. Read it beside margin, cash conversion and reinvestment.
- The 4-Factor Sector Score ranks research priority, not portfolio action. Management quality, catalysts and risks need equally fresh evidence before capital is deployed.
- An “all companies” line chart preserves completeness, but rank changes should be checked against reporting dates before drawing a conclusion.
- 3 companies draw at least one figure from a second data feed with too little overlapping history to cross-check against the primary source; they are marked unverified wherever those figures appear.
- 1 company is missing from the second-feed metrics by decision, not by absence: the two sources disagree, so nothing from the second is drawn. Read those rows as narrower evidence, never as a weaker business.
- Thin comparisons: Capital expenditure, Valuation have fewer than three usable current readings.
10 · the complete set
Which companies are included?
All 10 companies in the canonical Pharma - Others membership are listed below, largest market value first — nothing is silently dropped, even where a company reports too little to rank. 2 of these are no longer being priced, so their price and relative strength are frozen at the last traded week shown.
AHEAD means the company is beating the index by 5% or more over three months. LAGGING, FUNDAMENTALS UP means it is 20% or more behind over a year while its trailing twelve-month earnings grew 20% or more. Both rules are fixed and applied the same way in every sector.
| Company | Market value | Price | Priced to | Latest fundamentals | Source standing |
|---|---|---|---|---|---|
| Sun Pharma Advanced Research Company Ltd SPARCAHEAD19/26 WEEKS | ₹7.0K Cr | ₹216 | 2026-07-19 | Mar 2026 | Cross-checked |
| Unichem Laboratories Ltd UNICHEMLABAHEAD | ₹3.8K Cr | ₹537 | 2026-07-19 | Mar 2026 | Second feed withheld |
| Panacea Biotec Ltd PANACEABIOAHEAD | ₹2.7K Cr | ₹441 | 2026-07-19 | Mar 2026 | Cross-checked |
| Shukra Pharmaceuticals Ltd SHUKRAPHAR | ₹1.8K Cr | ₹41.4 | 2026-03-08 · not currently priced | Dec 2025 | Primary source only |
| TTK Healthcare Ltd TTKHLTCARE⚠ unverified | ₹1.5K Cr | ₹1,047 | 2026-07-19 | Mar 2026 | Includes unverified figures |
| Syncom Formulations (India) Ltd SYNCOMFLAGGING, FUNDAMENTALS UP⚠ unverified | ₹1.2K Cr | ₹13.1 | 2026-07-19 | Mar 2026 | Includes unverified figures |
| JOJO Ltd 531910 | ₹874 Cr | ₹253 | 2026-07-19 | Mar 2026 | Primary source only |
| Remus Pharmaceuticals Ltd REMUSAHEADLAGGING, FUNDAMENTALS UP⚠ unverified | ₹848 Cr | ₹720 | 2026-07-19 | Mar 2026 | Includes unverified figures |
| Madhuveer Com 18 Network Ltd MADHUVEER | ₹581 Cr | ₹228 | 2026-03-08 · not currently priced | Dec 2025 | Primary source only |
| Jenburkt Pharmaceuticals Ltd 524731 | ₹498 Cr | ₹1,128 | 2026-06-28 | Mar 2026 | Primary source only |
How each company's sources stand: 3 of 10 companies draw at least one figure from a second data feed that could not be cross-checked against the primary source, because the two do not share enough reported history to compare. Those figures are marked unverified wherever they appear. 1 of 10 companies has a second data feed that is known to disagree with the primary source, so nothing from it is drawn: Unichem Laboratories Ltd (UNICHEMLAB) — its two data sources disagree by up to 338% on reported income across 14 comparable periods, so its derived ratios are withheld.
Evidence and freshness
How was this comparison built?
This comparison is built from the reported filings of 10 Pharma - Others companies, normalized to a common ₹ scale and a shared quarter axis of up to 20 quarters each. Fundamentals run through Mar 2026 and market data through 2026-07-24. A second data feed fills gaps only after identity and scale reconciliation, and missing observations are never interpolated.
FundamentalsThrough Mar 2026 · up to 20 quarters per company
Market dataThrough 2026-07-24 · weekly price and relative-strength history
Derived metricsGrowth, changes, CAPEX intensity, net debt, guarded PEG and P/BV÷ROE are calculated only when their inputs are comparable.
Score confidenceMissing and stale evidence reduces confidence and pulls the 0–100 research-priority score toward neutral.
Source standing2 cross-checked · 7 unverified · 1 withheld, of 10 graded companies.
A second feed is read only after its reported income is matched against the primary source on at least three overlapping periods. Where the two agree the figures fill silently. Where there is too little shared history to compare, the figures are still drawn — they are the only evidence there is — and marked ⚠ unverified everywhere they appear. Where the two are known to disagree, nothing from the second feed is drawn and the affected company is named under the chart it is missing from. Every company's standing is listed in the register above.
Questions investors ask · short, speakable answers
Pharma - Others company comparison FAQs
These 17 answers restate the Pharma - Others comparison above in question form. Every one is computed from the same 10 companies and the same reported filings as the rankings and charts, current through Mar 2026. Price and relative-strength answers run through 2026-07-24. Nothing here is estimated, and none of it is a recommendation.
What is the Nifty Pharma - Others index?
The Nifty Pharma - Others index tracks India's listed Pharma - Others companies as a single basket. This page follows the same 10 companies and equal-weights them, so every company's weekly return counts once whatever it is worth, and the reading belongs to the Pharma - Others sector rather than to its largest constituent. Figures are as of Mar 2026.
Which are the best Pharma - Others stocks in India?
Ranked by this page's four-factor score, JOJO Ltd places first among 10 listed Pharma - Others companies, followed by Shukra Pharmaceuticals Ltd. That is a ranking of published data — earnings, quality, valuation and market behaviour as of Mar 2026 — and not a recommendation; Sector Alpha is not registered with SEBI as an investment adviser.
How many Pharma - Others stocks are listed in India?
This comparison covers 10 listed Pharma - Others companies in India, each above the size floor the site applies, with 20 quarters of reported figures per company where the filings exist. The full ranked list is on this page, as of Mar 2026.
Which Pharma - Others company is the biggest?
Unichem Laboratories Ltd is the largest, with trailing-twelve-month revenue of ₹2,202 crore, ahead of Sun Pharma Advanced Research Company Ltd at ₹1,879 crore. That covers 10 of 10 companies with comparable reporting through Mar 2026.
Which Pharma - Others company is growing fastest?
JOJO Ltd has the fastest revenue growth at 100% year on year, across 10 of 10 comparable companies. Fast growth off a small base is not the same as proven scale — check whether the rate holds across several quarters on the chart above before treating it as a trend.
Which Pharma - Others company has the best profit margins?
Sun Pharma Advanced Research Company Ltd has the highest operating margin at 96%, from 10 of 10 comparable companies. Sun Pharma Advanced Research Company Ltd shows the biggest recent improvement, at +292 percentage points. A high margin matters most when it is holding or rising, not when it is peaking.
Which Pharma - Others company makes the most profit?
Sun Pharma Advanced Research Company Ltd earns the most, at ₹1,553 crore of trailing-twelve-month net profit, from 10 of 10 comparable companies. JOJO Ltd has the fastest profit growth at 100%, though growth off a small or recovering profit base overstates how much has actually changed.
Which Pharma - Others company earns the highest return on capital?
Sun Pharma Advanced Research Company Ltd leads on return on capital employed at 164%, across 10 of 10 companies. Read it beside the length of its reported history: a high return that repeats for years is evidence of a durable business, while a single high reading can be a small capital base or one good year.
Which Pharma - Others company has the strongest balance sheet?
Syncom Formulations (India) Ltd carries the lowest comparable gross debt at ₹1 crore, from 10 of 10 companies. Absolute rupee debt alone does not settle it, because company scale differs — net debt and debt-to-equity in the chart above carry more information, and a very low-debt balance sheet can also mean under-investment.
Which Pharma - Others stock has the strongest price momentum?
Sun Pharma Advanced Research Company Ltd has the strongest relative strength against NIFTY 500. Relative strength answers last, after growth, quality and valuation: price can move well before the fundamentals confirm it, and sometimes without them confirming at all.
Which Pharma - Others company scores highest for research priority?
JOJO Ltd scores 65.6 out of 100 with 70.2% evidence confidence, from 30 points on growth and earnings, 14 on capital efficiency, 8.9 on valuation and 12.7 on relative strength. This ranks what deserves work next. It is not a buy recommendation, and management quality, catalysts and risk still need separate research.
How many Pharma - Others companies does this comparison cover, and over what period?
It compares 10 listed companies over up to 20 reported quarters of fundamentals and 10 fiscal years of capital allocation, ending Mar 2026, plus weekly price and relative-strength history. Membership is the full sector list — nothing is dropped for having thin data.
What is the total market cap of the Pharma - Others sector?
The 10 Pharma - Others companies on this page carry ₹20,827 crore of combined market value. Sun Pharma Advanced Research Company Ltd is the largest at ₹7,017 crore, about 34% of the sector's total on its own. Market value moves with price, so this reading is dated 2026-07-29.
What is the Pharma - Others sector's P/E ratio?
The median price-to-earnings ratio across the 10 Pharma - Others companies on this page is 22.9×, measured on the 9 that report a comparable figure. A sector-level history for this multiple is not held here, so this is a cross-section of today, not a comparison with the sector’s own past. Figures are as of 2026-07-29.
How is the Pharma - Others sector performing?
7 of the 10 covered Pharma - Others companies are beating NIFTY 500 on Mansfield relative strength. A 52-week sector-versus-index comparison is not available from the current market series for this sector, so it is not quoted. Readings are as of 2026-07-29.
Why are some values on this page blank?
A blank means that company did not report a comparable figure for that period, so nothing is shown. Missing observations are never interpolated, carried forward, or replaced with a similar-looking accounting line, and a company with missing evidence has its research score pulled toward neutral rather than being scored as bad.
Is this investment advice?
No. Every figure here is a deterministic calculation from reported company filings and market data, published for research. It contains no recommendation to buy or sell any security, does not account for your circumstances, and is not a substitute for advice from a licensed adviser.